Angiotensin-Converting Enzyme Inhibitors - Therapeutic use
Research News and Information

Monday, November 23, 2009

Clinical benefit of early reperfusion therapy in patients with ST-elevation myocardial infarction usually excluded from randomized clinical trials (results from the Maximal Individual Therapy in Acute Myocardial Infarction Plus [MITRA Plus] registry).

13 Oct 2009 Randomized clinical trials (RCTs) usually enroll selected patient populations that may not be representative for patients seen in everyday practice. Therefore, concerns have been raised regarding their external validity. For the present study we ... Read more...

Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.

3 Oct 2009 BACKGROUND: Chronic kidney disease (CKD) is an established risk factor for poor outcomes in heart failure (HF). Whether proteinuria provides additional prognostic information is not known. Renin-angiotensin blockade medications improve outcomes in ... Read more...

Quinaprilat: a review of its pharmacokinetics, pharmacodynamics, toxicological data and clinical application.

29 Sep 2009 BACKGROUND: Quinaprilat is an ACE inhibitor for intravenous use especially in patients with arterial hypertension or chronic heart failure. In contrast to the oral prodrug quinapril, it has not been approved for clinical application. OBJECTIVE: In ... Read more...

Latest indexed articles for 'Angiotensin-Converting Enzyme Inhibitors - Therapeutic use'

These are the very latest articles for this heading:

• ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses. 24 Oct 2009
• Clinical benefit of early reperfusion therapy in patients with ST-elevation myocardial infarction usually excluded from randomized clinical trials (results from the Maximal Individual Therapy in Acute Myocardial Infarction Plus [MITRA Plus] registry). 13 Oct 2009
• Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure. 3 Oct 2009
• Quinaprilat: a review of its pharmacokinetics, pharmacodynamics, toxicological data and clinical application. 29 Sep 2009
• Baseline differences in the HF-ACTION trial by sex. 29 Sep 2009
• Renal and retinal effects of enalapril and losartan in type 1 diabetes. 29 Sep 2009
• Renal and retinal effects of enalapril and losartan in type 1 diabetes. 29 Sep 2009
• [Hypertension in diabetes mellitus] 25 Sep 2009
• Regression of left ventricular mass by antihypertensive treatment: a meta-analysis of randomized comparative studies. 19 Sep 2009
• Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease. 19 Sep 2009
• Role of renin-angiotensin system blockade in patients with diabetes mellitus. 13 Sep 2009
• Angiotensin II, mechanotransduction, and pulsatile arterial hemodynamics in hypertension. 2 Sep 2009
• Lessons learned from the ONTARGET and TRANSCEND trials. 30 Aug 2009
• Optimizing management of hypertension with combination therapy: considerations for the nurse practitioner. 30 Aug 2009
• Progress in pediatric vasculitis. 30 Aug 2009
• Coronary calcium significantly affects quantitative analysis of coronary ultrasound: importance for atherosclerosis progression/regression studies. 30 Aug 2009
• Pharmacologic prevention of anthracycline-induced cardiomyopathy. 30 Aug 2009
• Should proteinuria reduction be the criterion for antihypertensive drug selection for patients with kidney disease? 30 Aug 2009
• Association between the use of 4 recommended drug categories and patient perceptions of health status following an ACS event. 30 Aug 2009
• Cost-effectiveness of ACE inhibitor therapy to prevent dialysis in nondiabetic nephropathy: influence of the ACE insertion/deletion polymorphism. 30 Aug 2009

See a longer list of these articles.

Technical information about 'Angiotensin-Converting Enzyme Inhibitors'

Definition: A class of drugs whose main indications are the treatment of hypertension and heart failure. They exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility.

Registry Number: 0

Descriptor UI: D000806

Alternative terms: Angiotensin-Converting Enzyme Inhibitors; Angiotensin Converting Enzyme Inhibitors; Antagonists, Angiotensin-Converting Enzyme; Antagonists, Angiotensin Converting Enzyme; Angiotensin I-Converting Enzyme Inhibitors; Angiotensin I Converting Enzyme Inhibitors; Inhibitors, Angiotensin-Converting Enzyme; Enzyme Inhibitors, Angiotensin-Converting; Inhibitors, Angiotensin Converting Enzyme; ACE Inhibitors; Kininase II Antagonists; Inhibitors, Kininase II; Kininase II Inhibitors; Inhibitors, ACE; Angiotensin-Converting Enzyme Antagonists; Angiotensin Converting Enzyme Antagonists; Enzyme Antagonists, Angiotensin-Converting; Antagonists, Kininase II;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Tree Number: D27.505.519.389.745.085;

Online Note: use TEPROTIDE to search ANGIOTENSIN I-CONVERTING ENZYME INHIBITOR 1991-93

History Note: 88; ANGIOTENSIN I-CONVERTING ENZYME INHIBITOR was see TEPROTIDE 1991-93

Technical Notes: protease inhib & antihypertensives; DF: ACE INHIB